Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,485 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,566 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04365179 | Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML | unknown | Phase 1 | 18 | Immune System Key LtdINDUSTRY | 1 | Jul 10, 2024 | clinicaltrials |
| NCT06362980 | A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations(EGFR) | unknown | Phase 1 | 20 | National Cancer Center, ChinaOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT03784066 | Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity(DUTRELASCO) | unknown | Phase 1 / Phase 2 | 21 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT02628405 | R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma | unknown | Phase 1 / Phase 2 | 30 | Academic and Community Cancer Research UnitedOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT04432857 | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | unknown | Phase 1 | 63 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 2 | Jun 27, 2024 | clinicaltrials |
| NCT06478381 | L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma | unknown | Phase 1 | 22 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 27, 2024 | clinicaltrials |
| NCT05060432 | Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors(TIG-006) | unknown | Phase 1 / Phase 2 | 153 | iTeos Belgium SAINDUSTRY | 6 | Jun 21, 2024 | clinicaltrials |
| NCT05444088 | Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 129 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 21, 2024 | clinicaltrials |
| NCT02977468 | Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer(Pembro/IORT) | unknown | Phase 1 | 15 | Eileen ConnollyOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT05422027 | Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma | unknown | Phase 1 / Phase 2 | 42 | Xia ZhongjunOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT05816499 | Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)(AK104IIT018) | unknown | Phase 1 / Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT05766748 | Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 30 | Cantex PharmaceuticalsINDUSTRY | 1 | Jun 14, 2024 | clinicaltrials |
| NCT05832892 | Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 41 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06372626 | Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. | unknown | Phase 1 / Phase 2 | 93 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jun 14, 2024 | clinicaltrials |
| NCT04818333 | A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 157 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 13, 2024 | clinicaltrials |
| NCT04215003 | A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC | unknown | Phase 1 / Phase 2 | 20 | Fudan UniversityOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT02061800 | CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant | unknown | Phase 1 / Phase 2 | 14 | Diane GeorgeOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06434090 | Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 74 | Sun Yat-sen UniversityOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT03275493 | CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia | unknown | Phase 1 / Phase 2 | 40 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | May 28, 2024 | clinicaltrials |
| NCT05605197 | U87 CART in Treatment of Advanced Solid Tumor | unknown | Phase 1 | 12 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | May 28, 2024 | clinicaltrials |
| NCT06427291 | Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC Patients | unknown | Phase 1 | 20 | Fudan UniversityOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT04134000 | Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)(BladderGATE) | unknown | Phase 1 | 40 | Fundacion OncosurNETWORK | 1 | May 21, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT06421610 | OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion. | unknown | Phase 1 | 20 | Odense University HospitalOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT03337087 | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | unknown | Phase 1 / Phase 2 | 18 | Academic and Community Cancer Research UnitedOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT05650580 | TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors | unknown | Phase 1 | 26 | Tarapeutics Science Inc.INDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT06173999 | A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma | unknown | Phase 1 / Phase 2 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT06412458 | IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma | unknown | Phase 1 | 9 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT05758610 | A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients | unknown | Phase 1 | 60 | Shengke Pharmaceuticals (Jiangsu) Limited, ChinaINDUSTRY | 1 | May 8, 2024 | clinicaltrials |
| NCT03292263 | ASCT With Nivolumab in Patients With Multiple Myeloma | unknown | Phase 1 / Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT05354102 | A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 | unknown | Phase 1 | 11 | Biomica Ltd.INDUSTRY | 1 | May 7, 2024 | clinicaltrials |
| NCT06081686 | Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer | unknown | Phase 1 / Phase 2 | 32 | Sinotau Pharmaceutical GroupINDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT06395337 | Multimodal Imaging in Rectal Cancer & Pancreatic Cancer(MIRCA & MIPAC) | unknown | Phase 1 / Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT05458544 | [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application(LUCIDA) | unknown | Phase 1 / Phase 2 | 26 | FutureChemINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT04499339 | A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma | unknown | Phase 1 / Phase 2 | 38 | Wuerzburg University HospitalOTHER | 3 | Apr 25, 2024 | clinicaltrials |
| NCT06384248 | Phase II Clinical Study of LTC004 in Patients With Advanced Sarcoma | unknown | Phase 1 / Phase 2 | 30 | LetolabINDUSTRY | 0 | Apr 25, 2024 | clinicaltrials |
| NCT05989724 | A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors | unknown | Phase 1 | 150 | Qurgen Inc.INDUSTRY | 1 | Apr 24, 2024 | clinicaltrials |
| NCT06367673 | Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia | unknown | Phase 1 | 24 | Zhejiang UniversityOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT05735028 | The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer | unknown | Phase 1 | 8 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05606380 | A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma | unknown | Phase 1 | 11 | Shanghai Henlius BiotechINDUSTRY | 1 | Apr 16, 2024 | clinicaltrials |
| NCT05240131 | A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). | unknown | Phase 1 / Phase 2 | 88 | Galecto Biotech ABINDUSTRY | 3 | Apr 12, 2024 | clinicaltrials |
| NCT05519293 | Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation | unknown | Phase 1 / Phase 2 | 76 | RedCloud BioINDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05552781 | H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC | unknown | Phase 1 / Phase 2 | 76 | RedCloud BioINDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06308406 | A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer | unknown | Phase 1 / Phase 2 | 54 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT04469127 | A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients.(Heroine01) | unknown | Phase 1 / Phase 2 | 100 | Advanced Imaging Projects, LLCINDUSTRY | 2 | Apr 10, 2024 | clinicaltrials |
| NCT06356701 | Tumor Nutritional Therapy in the First-line Treatment of Stage IV NSCLC | unknown | Phase 1 | 120 | The First Affiliated Hospital of Dalian Medical UniversityOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT04032964 | Dose Finding Study of L19TNF and Doxorubicin in Patients With STS(DOXO75) | unknown | Phase 1 | 2 | Philogen S.p.A.INDUSTRY | 1 | Apr 8, 2024 | clinicaltrials |
| NCT04573192 | A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression(GLIOSTAR) | unknown | Phase 1 / Phase 2 | 142 | Philogen S.p.A.INDUSTRY | 4 | Apr 8, 2024 | clinicaltrials |
| NCT05064618 | Investigator-initiated Clinical Trial of MIKE-1(MIKE-1) | unknown | Phase 1 / Phase 2 | 55 | Nagoya UniversityOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT04772235 | Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients(TOTEM) | unknown | Phase 1 | 32 | Instituto Oncológico Dr RosellOTHER | 1 | Apr 3, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jul 10, 2024source: clinicaltrials